1. Home
  2. CPF vs DRUG Comparison

CPF vs DRUG Comparison

Compare CPF & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Central Pacific Financial Corp New

CPF

Central Pacific Financial Corp New

HOLD

Current Price

$34.77

Market Cap

880.7M

Sector

Finance

ML Signal

HOLD

Logo Bright Minds Biosciences Inc.

DRUG

Bright Minds Biosciences Inc.

HOLD

Current Price

$88.66

Market Cap

707.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CPF
DRUG
Founded
1954
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Pharmaceuticals and Biotechnology
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
880.7M
707.1M
IPO Year
2011
2020

Fundamental Metrics

Financial Performance
Metric
CPF
DRUG
Price
$34.77
$88.66
Analyst Decision
Buy
Strong Buy
Analyst Count
2
6
Target Price
$37.00
$129.25
AVG Volume (30 Days)
108.2K
159.5K
Earning Date
04-29-2026
05-15-2026
Dividend Yield
3.39%
N/A
EPS Growth
45.18
N/A
EPS
0.78
N/A
Revenue
$51,817,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$4.62
N/A
P/E Ratio
$44.54
N/A
Revenue Growth
33.81
N/A
52 Week Low
$25.62
$23.18
52 Week High
$35.41
$123.75

Technical Indicators

Market Signals
Indicator
CPF
DRUG
Relative Strength Index (RSI) 60.76 56.16
Support Level $30.17 $72.06
Resistance Level $35.06 $91.69
Average True Range (ATR) 0.72 4.27
MACD -0.03 -0.52
Stochastic Oscillator 77.83 64.71

Price Performance

Historical Comparison
CPF
DRUG

About CPF Central Pacific Financial Corp New

Central Pacific Financial Corp operates in the financial services sector in the United States. It is a full-service commercial bank offering a broad range of banking products and services, including accepting time and demand deposits and originating loans. Bank's deposits are insured by the Federal Deposit Insurance Corporation (FDIC) up to applicable limits. The bank is not a member of the Federal Reserve System. The company's loans include commercial loans, construction loans, commercial and residential mortgage loans, and consumer loans. The company derives income from interest and fees on loans, interest on investment securities, and fees received in connection with deposits and other services. It operates in single segment which is Banking operations.

About DRUG Bright Minds Biosciences Inc.

Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Share on Social Networks: